心脏放疗剂量可预测食管鳞癌根治性同步放化疗后的生存
中位随访16.2个月,中位总生存18.4个月。心脏V5、V10、V20是总生存的独立预后因素,较低的心脏剂量与更长的生存和更低的症状性心脏不良事件累积发生率相关。
要点
- 心脏V5、V10、V20是食管鳞癌根治性同步放化疗后总生存的独立预后因素。
- 心脏V5≤94.3%、V10≤86.4%、V20≤76.9%的患者中位总生存更长。
- 较低心脏剂量组症状性心脏不良事件累积发生率更低,无事件者3年总生存率更高。
核心结论
- 心脏放疗剂量与食管鳞癌根治性同步放化疗后的生存呈负相关,应尽量减少心脏照射剂量。
主要发现
- 中位随访16.2个月(范围4.3-109.3),中位总生存18.4个月。
- 心脏V5、V10、V20是总生存的独立预后因素。
- 心脏V5≤94.3%者中位总生存24.7个月对16.3个月(p=0.0025),V10≤86.4%者24.8对16.9个月(p=0.0041),V20≤76.9%者20.0对17.2个月(p=0.047)。
- 心脏V5≤94.3%(p=0.017)、V10≤86.4%(p=0.02)、V20≤76.9%(p=0.0057)者症状性心脏不良事件累积发生率更低。
- 无心脏不良事件者3年总生存率33.8%对0%(p=0.03)。
关键数值与推荐
- 心脏V5≤94.3%、V10≤86.4%、V20≤76.9%与更长的中位总生存和更低的症状性心脏不良事件累积发生率相关。
临床怎么用
- 在食管鳞癌根治性同步放化疗的IMRT计划中应尽量降低心脏V5、V10、V20等剂量体积参数。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic significance of cardiac radiation dose in esophageal cancer after definitive concurrent chemoradiotherapy (CCRT) remains largely unknown. We aimed to investigate the association between cardiac dose-volume parameters and overall survival (OS) in esophageal squamous cell carcinoma (ESCC) after definitive CCRT. METHODS: One hundred and twenty-one ESCC patients undergoing definitive CCRT with intensity modulated radiotherapy technique between 2008 and 2018 were reviewed. Cardiac dose-volume parameters were calculated. Survival of patients and cumulative incidence of adverse events were estimated by the Kaplan-Meier method and compared between groups by the log-rank test. The prognostic significance of cardiac dose-volume parameters was determined with multivariate Cox proportional hazards regression analysis. RESULTS: Median follow-up was 16.2 months (range, 4.3-109.3). Median OS was 18.4 months. Heart V5, V10, and V20 were independent prognostic factors of OS. Median OS was longer for patients with heart V5 ≤ 94.3% (24.7 vs. 16.3 months, p = 0.0025), heart V10 ≤ 86.4% (24.8 vs. 16.9 months, p = 0.0041), and heart V20 ≤ 76.9% (20.0 vs. 17.2 months, p = 0.047). Lower cumulative incidence of symptomatic cardiac adverse events was observed among patients with heart V5 ≤ 94.3% (p = 0.017), heart V10 ≤ 86.4% (p = 0.02), and heart V20 ≤ 76.9% (p = 0.0057). Patients without symptomatic cardiac adverse events had a higher 3-year OS rate (33.8% vs. 0%, p = 0.03). CONCLUSIONS: Cardiac radiation dose inversely correlated with survival in ESCC after definitive CCRT. Radiation dose to the heart should be minimized.
引用
- Pao TH, Chang WL, Chiang NJ, et al. Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy. Radiat Oncol. 2020. PMID: 32962730. doi:10.1186/s13014-020-01664-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。